Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces it has entered into an agreement to acquire IsoTherapeutics Group, LLC (IsoTherapeutics), a specialty radiopharmaceutical development and bioconjugation firm, based in Angleton, Texas. Founded in 2005, IsoTherapeutics is a privately held, commercial-stage company, which provides radiochemistry and bioconjugation development and contract manufacturing services to many companies in the radiopharmaceutical industry, including Telix. In line with Telix’s continued investment in the vertical integration of supply chain, manufacturing and development capabilities, the acquisition is expected to further enhance Telix’s in-house drug development capabilities.
Read the full article: Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics //
Source: https://www.globenewswire.com/news-release/2024/02/26/2835518/0/en/Telix-Expands-U-S-Development-and-Manufacturing-Infrastructure-with-Acquisition-of-IsoTherapeutics.html